Targeting All BRAF Alterations: The (Re)-Search Continues | JCO Precision Oncology JCO Precision Oncology ASCO ascopubs.org/doi/10.1200/PO…

Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma [Apr 23, 2024] Kazandjian Ben Diamond, MD et al. Francesco Maura C. Ola Landgren, M.D. Clinical Cancer Research aacrjournals.org/clincancerres/… #mmsm #cagenome

After over 20 years caring for thousands of cancer patients, what would you do next?

In four days, I begin as Interim Chair of Radiation Oncology and Residency Program Director Tufts Medical Center. This new role will let me help through leadership, learning, and collaboration.

An interesting trend I found:

Among the top 10 national winners at the Intel/Westinghouse Science Fair from 1990 to 2002, 66% of them are now in academia.

Among the same group from 2003 to 2014, less than a third are academics.

On April 26, 2024, the FDA issued 3 draft guidance documents on eligibility criteria in cancer clinical trials to address:
📝 performance status
⌛ washout periods
💊 📊 concomitant medications and laboratory values
fda.gov/regulatory-inf… search 'eligibility'

#Myeloma Paper of the Day: Study of CHIP in AL #amyloidosis finds mutations at higher frequency (21%) vs. controls, DNMT3A was most frequent mutation, CHIP patients were enriched for t(11;14) & renal involvement, but not associated w/ worse outcomes: pubmed.ncbi.nlm.nih.gov/38652890/.

Thanks for retweeting our paper Robert Z. Orlowski ! Excited to present the strong work of my trainee Paolo Lopedote, soon to be City of Hope Marcel van den Brink Heme-Onc fellow, on CHIP in AL amyloidosis! Another fun collaboration with Niccolo Bolli .

My slides and key takeaways from 2 days of intense discussion at the FDA/IMS meeting on drug development in myeloma. Applies to other cancers as well. #MedTwitter FDA Oncology Myeloma Society

1) 15 new drugs approved for myeloma in the last 20 years! Incredible.

Great information- a must read! #mmsm

A cancer #drugshortage 'is not a problem that will fix itself through the power of the markets,” explains ASCO member Jason Westin, MD FACP.

Sign our Open Letter urging policymakers to act now to find solutions that will end this crisis: brnw.ch/21wJd5z #ASCOAdvocacy

If you agree that it’s time to end drug shortages, please share and sign this important letter from ASCO

Cancer prevention research is directed towards improving current treatments & survival rates among people w/cancer & improving their quality of life. Learn more about NRG’s cancer prevention trials currently enrolling participants: @FORTEStudy & SOROCk. nrgoncology.org

Letting a bunch of people who have never treated a patient or gone to medical school make decisions on how we practice medicine and take care of patients in this country is bonkers…

BREAKING: Supreme Court that blocked vaccine mandates & struck down quarantine orders suddenly VERY concerned about immunity.

Inspiration, Community, Insight. Experience #ASCO24 - a unique blend of scientific discovery and an innate community spirit.

Please read and share.
End ABIM MOC.

Honored to be in Dublin w/ Julie Gralow ASCO at #EuroAmericanCancerForum2024 . I've so enjoyed participating in today's sessions on global cancer care: from comfort to cure, accelerating progress together, and empowering transatlantic cooperation. #CancerHasNoBorders

Early Outpatient Treatment for Covid-19 with Convalescent Plasma [Mar 30, 2022] David J Sullivan et al. NEJM ow.ly/4SPa50IwB6P #NCT04373460 #COVID19 CP #COVID19

Safety of COVID-19 convalescent plasma: A definitive systematic review and meta-analysis of randomized controlled trials [Dec 29, 2023] Franchini et al. Daniele Focosi, MD PhD MSc Transfusion onlinelibrary.wiley.com/doi/10.1111/tr… #COVID19CP AABB Arturo Casadevall Jack Senefeld Michael Joyner

#AMLsm #leusm #PrecisionMedicine